

PATENT


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No.: HERDEIS-2

In re Application of:)
CLAUS HERDEIS & CHRISTIAN EDWIN WEIS)
Appl. No.: 10/616,587)
Filed: July 10, 2003)
For: METHOD OF TREATMENT FOR ACNE, ROSACEA AND ULCERS WITH TAURILIDINE AND/OR TAURULTAM IN A PHARMECEUTICAL COMPOSITION)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on <u>September 5, 2003</u> (Date)	
<u>Ursula B. Day</u> (Name of Registered Representative)	
 Signature	<u>Sept 5 2003</u> Date of Signature

S I R:

In accordance with 37 C.F.R. 1.56, applicant wishes to call the attention of the Examiner to the references as listed on enclosed form PTO-1449 most of which were cited in the instant specification and . Applicant does not admit that any of the cited documents constitutes prior art against the pending application.

Copies of these references are submitted herewith along with form PTO-1449. The Examiner is requested to initial the attached form PTO-1449 and to return a copy of the initialed document to the undersigned as an indication that the attached references have been considered and made of record.

- ☒ This Information Disclosure Statement is filed within three months of the filing date of a national application other than a continued prosecution application under 1.53(d), so that no fee under 37 C.F.R. §1.97 is due.
- ☐ This Information Disclosure Statement is filed within three months of the date of entry of the national stage as set forth in 1.491 in an international application, so that no fee under 37 C.F.R. §1.97 is due.
- ☐ This Information Disclosure Statement is filed before the mailing of a first Office Action on the merits, so that no fee under 37 C.F.R. §1.97 is due.
- ☐ This Information Disclosure Statement is filed before the mailing of a first Office Action after the filing of a request for continued examination under §1.114, so that no fee under 37 C.F.R. §1.97 is due.
- ☐ This Information Disclosure Statement is filed after the issuance of a first office but before issuance of a final action under §1.113, or a notice of allowance under §1.311.
- ☐ This Information Disclosure Statement is submitted after the mailing of a final action or a notice of allowance, but before payment of the issue fee.
- ☐ The undersigned submits the following statement requesting consideration of this statement:

The undersigned hereby states:


- ☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement;
- ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the information disclosure statement.
- ☐ The fee of \$180.00 set forth in 1.17(p).
- ☐ The Commissioner is hereby authorized to charge the fee as set forth in 1.17(p), and any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-0502.
- ☐ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-0502.

The above-identified application discloses and claims an invention patentable over this prior art.

Entry of the references above set forth into the file of the above application is believed to be in order and is respectfully requested.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-0502.

Respectfully submitted

By: 
Ursula B. Day
Attorney for Applicant
Reg. No. 47,296

Date: September 5, 2003
350 Fifth Avenue
Suite 4714
New York, N.Y. 10118
(212) 244-5500
UBD:be



Form PTO-1449

U.S. Department of Commerce
Patent and Trademark Office

INFORMATION DISCLOSURE CITATION

Attorney's Docket N . HERDEIS-2	Applicant CLAUS HERDEIS ET AL.	Appl. No. 10/616,587
Filing Date July 10, 2003	Group	Examiner

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date, if appropriate
	3,423,408	01-21-1969	Pfirmann			
	5,889,183	03-30-1999	Herdeis			
	4,107,305	08-15-1978	Pfirmann			
	4,337,251	06-29-1982	Pfirmann			
	4,587,268	05-06-1986	Pfirmann			
	4,604,391	08-05-1986	Pfirmann			
	4,626,536	12-02-1986	Pfirmann			
	4,772,468	09-20-1988	Pfirmann			
	4,882,149	11-21-1989	Spector			
	6,251,896	06-26-2001	Costin			
	6,350,742	02-26-2002	Costin			
	6,436,926	08-20-2002	Costin			
	6,555,534	04-29-2003	Costin			
	US2002/0049200	04-25-2002	Calabresi et al.			
	5,077,281	12-31-1991	Reinmüller			
	US2002/0161003	10-31-2002	Costin			

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation
482 713	01-30-1970	Switzerland			No
0 253 662	11-14-1990	Europe			Yes
EP 1 066 830	01-10-2001	Europe			Yes
WO 90/06138	06-14-1990	PCT			Yes
WO 92/000743	01-23-1992	PCT			Yes
WO 94/03174	02-17-1994	PCT			Yes
WO 98/52572	11-26-1998	PCT			Yes
DE 100 02 304	07-26-2001	Germany			No
DE 198 14 358	10-07-1999	Germany			No
DE 41 37 544	05-13-1993	Germany			No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Torres-Viera et al: "Activities of Taurolidine In Vitro and in Experimental Enterococcal Endocarditis, in: Antimicrobial Agents and Chemotherapy, June 2000, p. 1720-1724
	"Arzneimittel und Therapie", in: Deutsche Apothekerzeitung, July 10, 21999. 43-46

Examiner:

Date considered:

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.